It’s being reported that Israel may have discovered a cure for cancer! And, it turns out its not just a cure for certain forms of cancer, but a complete cure! The potential groundbreaking treatment is called ‘MuTaTo,” which is the abbreviation for, “multi-target toxin.”
Dan Aridor who is the chairman of the board for Accelerated Evolution Biotechnologies Ltd., said, “We believe we will offer in a year’s time a complete cure for cancer. Our cancer cure will be effective from day one. And will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.”
Too many of us have known someone who fought cancer valiantly but then succumbed to its deadliness. Jerusalem Post says, “An estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. Further, every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease).”
But if what Dan Aridor and his company are saying is true then cancer deaths may disappear!
The MuTaTo Treatment
The Jerusalem Post said, “MuTaTo is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order. The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.”
CEO of AEBi Dr. Ilan Morad said that the company’s technique of MuTaTo, “made sure that the treatment will not be affected by mutations. Cancer cells can mutate in such a way that targeted receptors are dropped by the cancer. The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used. Instead of attacking receptors one at a time, we attack receptors three at a time. Not even cancer can mutate three receptors at the same time.”
AEBi is currently writing patents on specific peptides in MuTaTo. The company is about to start numerous clinical trials that will be completed within a few years. But MuTaTo treatment will be made available in specific cases.